FEBRUARY 2014: Prana Biotechnology will hold an investor conference call and webcast for professional investors on Wednesday 19th February at 9.30am Australian Eastern Daylight Savings Time (Tuesday 18th February US EST 5.30pm; US PST 2.30pm) to discuss the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.
JANUARY 2014: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse.
MELBOURNE, December 11, 2013: Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease (AD) Extension trial.
MELBOURNE, December 9, 2013: Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease (AD) clinical trial.
Prana Biotechnology (ASX:PBT/
NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in
neurodegenerative disease, will present at The 2013 Therapeutic Area Partnerships (TAP)
meeting in Boston, USA.
Prana Biotechnology (NASDAQ:PRAN;
ASX:PBT) has today provided an update on the IMAGINE Phase 2 trial for Alzheimer’s
Disease and is pleased to report that 29 patients of the 42 patients originally enrolled into the
trial have now completed treatment.
Prana Biotechnology has today announced the publication of an article in the peer reviewed Aging Cell showing the effects of PBT2 on neurogenesis and in reversing the memory and learning losses associated with the aging process, in normal (ie non transgenic) old mice.
Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.
Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that the first patient has been dosed in the 12-month open-label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial.
Receive news from Alterity Therapeutics
